
    
      Because ACT-541468 appears to be mainly metabolized by CYP3A4, it is deemed of interest to
      investigate the potential influence of diltiazem, a well-known CYP3A4 inhibitor on the
      pharmacokinetic profile of ACT-541468.

      Safety of the concomitant administration of the two drugs will also be assessed
    
  